Open Access. Powered by Scholars. Published by Universities.®

Digital Commons Network™

Open Access. Powered by Scholars. Published by Universities.®

2025

Discipline
Institution
Keyword
Publication
Publication Type
File Type

Articles 158761 - 158763 of 158763

Full-Text Articles in Entire DC Network

Folic Acid-Decorated Lipidic Nanocapsules Co-Loaded With Atorvastatin And Curcumin To Enhance Glioma Targeting In Mice, Mahitab Bayoumi, John Youshia, Osama Abdelkawy, Sara Abdelgaber, Mona Arafa, Maha Nasr, Omaima Sammour Jan 2025

Folic Acid-Decorated Lipidic Nanocapsules Co-Loaded With Atorvastatin And Curcumin To Enhance Glioma Targeting In Mice, Mahitab Bayoumi, John Youshia, Osama Abdelkawy, Sara Abdelgaber, Mona Arafa, Maha Nasr, Omaima Sammour

Pharmacy

Background: Glioma remains an intractable and highly aggressive brain tumor, mainly due to the daunting obstacle presented by the blood-brain barrier (BBB). To overcome this challenge and enhance therapeutic efficacy, a dual-drug delivery system was engineered. This system co-encapsulated curcumin, a nutraceutical with multitargeted anticancer potential, with atorvastatin calcium, a repurposed anticancer agent, within lipidic nanocapsules (LNCs). Methods: LNCs were prepared via the phase inversion temperature method and optimized using a Box–Behnken design. The optimized LNCs were subsequently functionalized with folic acid (FA) to enable active targeting. FA-LNCs were characterized using, XPS, TEM, in vitro release, and MTT cytotoxicity …


The Landscape Of Cyclin‑Dependent Kinase 4/6 Inhibitors In Solid Malignancies: Emphasis On Immunotherapy Combinatorial Strategies, Maha R.A. Abdollah, Sara A. Hussein, Ahmed H. Saadawy, Eman Badr, Neamtullah Wael, Rasha M. Allam, Ahmed M. Al‑Abd, Ana Maria Roncero Sanchez, Mai Tolba Jan 2025

The Landscape Of Cyclin‑Dependent Kinase 4/6 Inhibitors In Solid Malignancies: Emphasis On Immunotherapy Combinatorial Strategies, Maha R.A. Abdollah, Sara A. Hussein, Ahmed H. Saadawy, Eman Badr, Neamtullah Wael, Rasha M. Allam, Ahmed M. Al‑Abd, Ana Maria Roncero Sanchez, Mai Tolba

Pharmacy

Given the pivotal role of CDK4/6 deregulation in the pathogenesis of various malignancies, CDK4/6 inhibitors have been incorporated into cancer treatment protocols. Beyond their antiproliferative effects, these inhibitors exhibit prominent immunomodulatory properties. Preclinical data indicated that CDK4/6 inhibitors enhance the tumor cell antigen presentation capacity and restrict the proliferation of immunosuppressive regulatory T-cells. Furthermore, studies showed that CDK4/6 inhibitors could enhance the development of memory T-cell in vivo in melanoma mouse models and in the clinical setting in breast cancer (BC) patients. In silico analysis identified 225 protein targets for CDK4/6 inhibitors involved in 57 immune-related pathways which further supported …


Corchorus Olitorius Exhibits Antiproliferative Potential Supported By Metabolic Profiling And Integrative Biological Analyses, Maha R.A. Abdollah, Salma Sameh, Ahmed Elissawy, Eman Al-Sayed, Rola Labib, Lan Ye, Fang-Rong Chang, Abdel Nasser B. Singab Jan 2025

Corchorus Olitorius Exhibits Antiproliferative Potential Supported By Metabolic Profiling And Integrative Biological Analyses, Maha R.A. Abdollah, Salma Sameh, Ahmed Elissawy, Eman Al-Sayed, Rola Labib, Lan Ye, Fang-Rong Chang, Abdel Nasser B. Singab

Pharmacy

Herbal nutraceuticals could be employed as alternative or complementary routes for alleviating cancer. Corchorus olitorius (Malvaceae) was employed traditionally in the management of tumors. The study aimed to investigate the antiproliferative activity of C. olitorius leaves. In vitro cytotoxic and anti-angiogenic activities of C. olitorius were estimated. The bioactive fraction was subjected to in vivo study on BALB/ c female mice using Ehrlich Ascites Carcinoma model. UPLC-ESI-MS/MS analysis was done to determine the phytometabolites followed by in silico studies on the major identified compounds. The bioactive fraction possessed potent in vitro activity against A549 cells with IC50 = 7.8 µg/mL …